Enterprise AI Analysis
Novel Therapeutic Strategy Identified for Endocrine-Resistant ERα-Positive Breast Cancer Through Targeting ANT2.
This study leveraged chemoproteomics and cheminformatics to identify Adenine Nucleotide Translocase 2 (ANT2) as a direct target of perillyl alcohol (POH), a natural compound with antitumor effects. POH inhibits ANT2, leading to reduced ERα expression, impaired fatty acid elongation, and lipid droplet accumulation, effectively suppressing growth in endocrine-resistant breast cancer cells. In silico screening further identified Venetoclax and Nystatin as potential ANT2 inhibitors, suggesting a repurposing opportunity for these agents against resistance mechanisms involving ANT2 and lipid metabolism.
Executive Impact & Key Findings
Cutting-edge research reveals new pathways to overcome drug resistance in breast cancer. Our analysis translates these complex findings into actionable intelligence for your enterprise.
0
ERα-Positive BC Percentage
0
Patients with Recurrence (Tamoxifen)
0
HR for High ANT2 Expression (RFS)
0
ELOVL6 / ELOVL7 Correlation with MKI67 (R value)
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Perillyl alcohol (POH), a monoterpene, directly targets ANT2, a mitochondrial inner membrane protein mediating ATP/ADP exchange. This interaction leads to reduced ERα protein levels and suppresses cell growth in ERα-positive breast cancer cells. POH also significantly reduces intracellular ATP levels, impairing energy homeostasis critical for cancer cell survival and proliferation. This provides a novel mechanistic link between ANT2 inhibition and ERα regulation, offering a new avenue for therapeutic intervention.
High ANT2 expression is significantly correlated with poor prognosis and clinical aggressiveness in ERα-positive breast cancer, particularly in Luminal B subtypes. ANT2 depletion or POH treatment suppresses fatty acid elongation-related genes (like ELOVL6 and ELOVL7) and leads to intracellular lipid droplet accumulation in Fulvestrant-resistant cells. This suggests that ANT2, by influencing fatty acid elongation and lipid metabolism, plays a crucial role in endocrine resistance, making it a viable target to overcome acquired resistance.
In silico screening identified Venetoclax and Nystatin as potential ANT2 pore binders. Both compounds demonstrated tumor-suppressive effects against ERα-positive and endocrine-resistant breast cancer cells, mimicking the effects of POH or ANT2 depletion by reducing ERα levels and inducing lipid droplet accumulation. Notably, ANT2 knockdown enhanced sensitivity to Venetoclax, supporting its functional link to ANT2 inhibition. This highlights the potential for repurposing existing FDA-approved drugs to target ANT2 in endocrine-resistant BC.
0
High ANT2 expression shows a 1.8x higher risk of relapse in ER-positive, HER2-negative BC patients.
Enterprise Process Flow
POH identified as ERα reducer
→
Chemoproteomics links POH to ANT2
→
MD simulations confirm POH-ANT2 binding
→
ANT2 depletion reduces ERα, inhibits growth
→
ANT2 correlated with poor prognosis
→
POH suppresses endocrine-resistant cells
→
Fatty acid elongation implicated
→
In silico screen finds Venetoclax & Nystatin
→
Repurposed drugs validate ANT2 targeting
| Treatment | Effect on MCF7 Cells | Effect on Resistant Cells (TAMR-7/182R-1) | Key Mechanism |
|---|---|---|---|
| Tamoxifen | Inhibits growth | Minimal effect | ERα competition |
| Fulvestrant | Inhibits growth | Effective in TAMR-7, not 182R-1 | ERα degradation |
| POH | Inhibits growth (more potently) | Strongly inhibits growth | ANT2 targeting, ERα reduction, lipid droplet accumulation |
| Venetoclax / Nystatin | Inhibits growth | Inhibits growth | Potential ANT2 inhibition, ERα reduction, lipid droplet accumulation |
Impact of ANT2 Targeting on Lipid Metabolism in Resistant BC
This study revealed a critical link between ANT2 and lipid metabolism in endocrine-resistant breast cancer. Fulvestrant-resistant 182R-1 cells, which exhibit reduced ERα expression and high ANT2, showed significant upregulation of fatty acid elongation-related genes (ELOVL6, ELOVL7). Both ANT2 depletion via siRNA and POH treatment led to a marked accumulation of intracellular lipid droplets and suppressed colony formation in these resistant cells. This indicates that targeting ANT2 disrupts the fatty acid elongation pathway, shifting resistant cells towards lipid storage and inhibiting their proliferative capacity. This metabolic vulnerability offers a promising therapeutic angle, especially for patients who have developed resistance to conventional endocrine therapies.
- ELOVL6 Upregulation in Luminal B: Significant
- Lipid Droplet Accumulation: Increased
- Colony Formation: Suppressed
Calculate Your Potential ROI with AI
Understand the quantifiable impact our AI solutions can have on your research and development efforts. Adjust the parameters to see your projected annual savings and reclaimed hours.
Projected Annual Savings
$0
Annual Hours Reclaimed
0
Your AI Implementation Roadmap
A phased approach to integrate ANT2-targeting strategies into your oncology pipeline, from preclinical validation to clinical application.
Phase 1: Target Validation & Preclinical Proof-of-Concept
Establish the direct binding of novel compounds to ANT2 using biophysical assays (e.g., surface plasmon resonance) and confirm in vitro and in vivo efficacy in diverse endocrine-resistant ERα-positive BC models. Further elucidate the specific molecular mechanisms linking ANT2 inhibition to ERα stability and lipid metabolism, including comprehensive lipidomic profiling.
Phase 2: Biomarker Development & Patient Stratification
Identify and validate predictive biomarkers, such as ANT2 expression levels or fatty acid elongation signatures (ELOVL6, ELOVL7), to accurately stratify patients who are most likely to benefit from ANT2-targeting therapies. Develop robust diagnostic assays for clinical implementation.
Phase 3: Clinical Trials with Repurposed Agents & Novel Inhibitors
Initiate early-phase clinical trials for repurposed ANT2 inhibitors (e.g., Venetoclax) in combination with existing endocrine therapies, focusing on biomarker-selected patient populations. Simultaneously, advance the development of novel, highly specific ANT2 inhibitors with improved pharmacokinetic profiles and reduced off-target effects, aiming for standalone or combination therapies.
Ready to Transform Breast Cancer Treatment?
Explore how our AI-driven insights can accelerate your oncology research and drug development initiatives. Book a personalized consultation to discuss integrating ANT2-targeting strategies into your pipeline.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat